PARP1 and pancreatic neoplasm: In addition to driving sensitivity to platinum-based agents, HR deficiency forms a synthetic lethal relationship with small molecule inhibitors of poly (ADP ribose)-polymerase (PARP), and PARP inhibitors are now FDA approved for HR-deficient breast, ovarian, prostate, and pancreatic tumors.